Emerging strategies include TERT promoter inhibition using oligonucleotide antagonists such as GRN163L, telomerase splicing modulation through NOVA1-dependent alternative splicing blockade, and senescence-targeted therapies that combine senolytics (navitoclax) with SASP pathway inhibitors to mitigate pro-tumorigenic microenvironment effects, all of which represent promising approaches to advance lung cancer treatment (Shown in Figure 1) (43). The gene discussed is TERT; the disease is lung carcinoma.